Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan:19:128-132.
doi: 10.1016/j.jtos.2020.05.003. Epub 2020 May 20.

The effects of systemic cyclosporine in acute Stevens-Johnson syndrome/toxic epidermal necrolysis on ocular disease

Leangelo N Hall  1 , Swapna S Shanbhag  2 , Ramy Rashad  3 , James Chodosh  1 , Hajirah N Saeed  4
Affiliations

The effects of systemic cyclosporine in acute Stevens-Johnson syndrome/toxic epidermal necrolysis on ocular disease

Leangelo N Hall et al. Ocul Surf. 2021 Jan.

Abstract

Purpose: To evaluate the effect of systemic cyclosporine (CsA) on ocular disease in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) patients.

Methods: In this retrospective, comparative cohort study at a single center, patients with a diagnosis of SJS/TEN and with at least 3 months of follow up were divided into two groups: those who received systemic CsA and those who did not receive systemic CsA. Best-corrected visual acuity (BCVA) and chronic ocular surface complications score (COCS) at final follow-up were compared between the two groups.

Results: The median age and follow-up period of patients was 29 years (range, 1.5-71 years) and 16.8 months (range, 3.67-91.58 months), respectively. BCVA, COCS, meibomian gland dysfunction, limbal stem cell deficiency, and the need for mucous membrane grafting and scleral lenses were not significantly different between patients who received systemic CsA as compared to patients who did not receive systemic CsA.

Conclusions: In this small cohort of patients with SJS/TEN, we could identify no association between the use of systemic CsA as a component of their initial therapy and chronic ocular complications.

Keywords: Cyclosporine; Ocular surface disease; Stevens-johnson syndrome; Toxic epidermal necrolysis.

PubMed Disclaimer

References

    1. Yetiv JZ, Bianchine JR, Owen JA Jr. Etiologic factors of the Stevens- Johnson syndrome. South Med J 1980;73:599–602 - PubMed
    1. Choy AC, Yarnold PR, Brown JE, et al. Virus induced erythema multi- forme and Stevens-Johnson syndrome. Allergy Proc 1995;16:157–61 - PubMed
    1. Stevens D, Swift PG, Johnston PG, et al. Mycoplasma pneumoniae in- fections in children. Arch Dis Child 1978;53:38–42 - PMC - PubMed
    1. Power William J., et al. “Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum.” Ophthalmology 102.11 (1995): 1669–1676. - PubMed
    1. Saeed Hajirah N., and Chodosh James. “Ocular manifestations of Stevens–Johnson syndrome and their management.” Current opinion in ophthalmology 27.6 (2016): 522–529. - PubMed

Publication types